See more : Mohammed Hasan AlNaqool Sons Co. (9514.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Eris Lifesciences Limited (ERIS.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eris Lifesciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shurgard Self Storage Ltd (SHURB.XD) Income Statement Analysis – Financial Results
- hmvod Limited (8103.HK) Income Statement Analysis – Financial Results
- MAC2.L,0P0001LZZQ,0 (MAC2.L) Income Statement Analysis – Financial Results
- USA Compression Partners, LP (USAC) Income Statement Analysis – Financial Results
- StratoComm Corporation (STCO) Income Statement Analysis – Financial Results
Eris Lifesciences Limited (ERIS.BO)
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, anti-infective, blood related, cardiovascular, dermatology, gastrointestinal, gastroenterology, haematinics, hormones, nero/ central nervous system, neuropsychiatry, otologicals, pain/analgesics, respiratory, stomatologicals, cosmetology, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. The company offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.91B | 16.62B | 13.26B | 11.93B | 10.58B | 9.67B | 8.27B | 7.49B | 5.97B | 5.46B | 5.09B | 3.93B |
| Cost of Revenue | 9.66B | 3.57B | 2.61B | 2.42B | 1.79B | 1.55B | 1.36B | 1.07B | 1.01B | 961.74M | 1.00B | 750.33M |
| Gross Profit | 10.25B | 13.05B | 10.65B | 9.51B | 8.79B | 8.12B | 6.91B | 6.42B | 4.96B | 4.49B | 4.08B | 3.18B |
| Gross Profit Ratio | 51.47% | 78.51% | 80.33% | 79.72% | 83.11% | 83.96% | 83.53% | 85.71% | 83.15% | 82.37% | 80.28% | 80.91% |
| Research & Development | 57.18M | 61.00M | 327.38M | 50.92M | 41.96M | 41.12M | 7.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 714.79M | 471.75M | 504.09M | 430.35M | 352.91M | 317.71M | 335.11M | 362.82M | 332.10M | 362.33M | 318.47M | 309.23M |
| Selling & Marketing | 1.79B | 1.39B | 821.98M | 882.43M | 1.31B | 1.04B | 837.32M | 621.31M | 645.06M | 541.60M | 983.40M | 516.52M |
| SG&A | 4.79B | 1.86B | 1.33B | 1.31B | 1.66B | 1.35B | 1.17B | 984.13M | 977.16M | 903.93M | 1.30B | 825.75M |
| Other Expenses | 238.15M | 12.44M | 10.36M | 4.55M | 36.62M | 17.40M | 7.42M | 1.58M | 170.00K | 780.00K | 0.00 | 40.00K |
| Operating Expenses | 4.94B | 8.82B | 6.40B | 5.62B | 5.56B | 5.01B | 3.94B | 3.96B | 3.42B | 3.43B | 3.14B | 2.31B |
| Cost & Expenses | 14.91B | 12.39B | 9.01B | 8.04B | 7.35B | 6.56B | 5.31B | 5.03B | 4.43B | 4.40B | 4.15B | 3.06B |
| Interest Income | 70.10M | 22.99M | 60.98M | 22.85M | 16.06M | 10.96M | 9.96M | 8.56M | 4.18M | 840.00K | 1.70M | 2.76M |
| Interest Expense | 848.01M | 261.68M | 41.46M | 18.02M | 21.62M | 228.95M | 105.50M | 10.33M | 1.20M | 180.00K | 2.46M | 7.12M |
| Depreciation & Amortization | 1.83B | 1.17B | 647.05M | 429.85M | 502.58M | 363.54M | 256.42M | 227.61M | 203.56M | 155.14M | 47.68M | 34.85M |
| EBITDA | 6.99B | 5.48B | 5.11B | 4.39B | 3.84B | 3.77B | 3.48B | 2.93B | 1.68B | 1.25B | 1.03B | 911.81M |
| EBITDA Ratio | 35.08% | 32.66% | 37.46% | 36.42% | 35.81% | 36.19% | 39.22% | 36.06% | 28.82% | 22.30% | 19.50% | 23.20% |
| Operating Income | 5.18B | 4.29B | 4.31B | 3.96B | 3.27B | 3.11B | 2.97B | 2.47B | 1.54B | 1.06B | 944.32M | 876.96M |
| Operating Income Ratio | 26.02% | 25.84% | 32.53% | 33.22% | 30.95% | 32.15% | 35.95% | 32.91% | 25.83% | 19.45% | 18.56% | 22.31% |
| Total Other Income/Expenses | -869.33M | -248.41M | 108.43M | -16.73M | 78.60M | 64.06M | 157.47M | 238.24M | -1.68B | 34.42M | 40.52M | -34.76M |
| Income Before Tax | 4.31B | 4.05B | 4.42B | 3.94B | 3.31B | 3.17B | 3.12B | 2.70B | 1.54B | 1.09B | 983.25M | 831.39M |
| Income Before Tax Ratio | 21.66% | 24.35% | 33.34% | 33.08% | 31.31% | 32.81% | 37.75% | 36.08% | 25.87% | 20.06% | 19.32% | 21.15% |
| Income Tax Expense | 341.85M | 304.83M | 364.09M | 393.62M | 348.43M | 262.11M | 172.51M | 237.80M | 195.87M | 201.56M | 277.88M | 246.99M |
| Net Income | 3.92B | 3.82B | 4.06B | 3.55B | 2.96B | 2.91B | 2.94B | 2.47B | 1.34B | 892.34M | 704.19M | 581.98M |
| Net Income Ratio | 19.68% | 23.00% | 30.62% | 29.78% | 28.02% | 30.07% | 35.56% | 32.93% | 22.37% | 16.36% | 13.84% | 14.81% |
| EPS | 28.82 | 28.10 | 29.89 | 26.16 | 21.61 | 21.15 | 21.39 | 17.95 | 9.71 | 6.49 | 5.12 | 4.23 |
| EPS Diluted | 28.79 | 28.07 | 29.88 | 26.14 | 21.59 | 21.13 | 21.39 | 17.95 | 9.71 | 6.49 | 5.12 | 4.23 |
| Weighted Avg Shares Out | 136.01M | 135.98M | 135.87M | 135.78M | 137.19M | 137.52M | 137.50M | 137.50M | 137.50M | 137.50M | 137.50M | 137.50M |
| Weighted Avg Shares Out (Dil) | 136.17M | 136.17M | 135.91M | 135.88M | 137.30M | 137.64M | 137.50M | 137.50M | 137.50M | 137.50M | 137.50M | 137.50M |
Source: https://incomestatements.info
Category: Stock Reports